DexCom announced that its latest registry study, presented at the 19th annual Advanced Technologies and Treatments for Diabetes (ATTD) conference in Barcelona, found that long‑term use of the G7 continuous glucose monitoring system leads to clinically significant weight loss and a 0.5% reduction in the Glucose Management Indicator (GMI) over one year for patients with type 2 diabetes who are not on insulin. The study also reported improved time‑in‑range metrics, indicating better overall glucose control.
The findings were disclosed on March 10 2026, just before the ATTD conference began on March 11. DexCom’s G7 15‑day system, which received FDA approval on April 10 2025 and launched in the U.S. on December 1 2025, is the product evaluated in the registry. The study’s results reinforce the clinical value of the G7 platform beyond the insulin‑dependent population.
These data support DexCom’s broader strategy to expand CGM access to the non‑insulin type 2 market, a segment that represents a large, underserved patient base. By demonstrating tangible health benefits, the study provides evidence that could drive new payer coverage decisions and accelerate user adoption, thereby strengthening DexCom’s competitive position against rivals such as Abbott. The company’s ongoing development of the Stelo over‑the‑counter biosensor further underscores its commitment to this market segment.
In a statement, DexCom president and CEO Jake Leach said, “The data presented at ATTD reinforces the need for Dexcom CGM to become the standard of care for all people with Type 2 diabetes, including those not using insulin. That growing body of evidence, combined with our continued innovation across the Dexcom portfolio, reflects our broader ambition to transform diabetes care and advance metabolic health worldwide.” Leach also highlighted the potential Medicare coverage expansion for type 2 non‑insulin users, which could open access to CGM for nearly 12 million people.
The study’s implications extend beyond immediate clinical outcomes. DexCom’s CGM technology is increasingly viewed as complementary to the growing use of GLP‑1 drugs for diabetes management, and the company’s educational initiatives, such as the Dexcom Academy, aim to support healthcare professionals in adopting CGM for a wider patient population. Together, these efforts position DexCom to capture a larger share of the metabolic health market and drive long‑term growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.